Literature DB >> 16493470

Expedient synthesis and structure-activity relationships of phenanthroindolizidine and phenanthroquinolizidine alkaloids.

Ta-Hsien Chuang1, Shiow-Ju Lee, Cheng-Wei Yang, Pei-Lin Wu.   

Abstract

The total synthesis of alkaloids phenanthroindolizidine 1a, tylophorine 1b, and phenanthroquinolizidine 1c, has been achieved in 46%, 49%, and 42% overall yield, respectively, starting from the corresponding phenanthrene-9-carboxaldehyde. Compound exhibited potent inhibition activity in three human cancer cell lines, with IC(50) values ranging from 104 to 130 nM. The structure-activity relations of these alkaloids and some of their synthetic intermediates against the three cell lines were also described.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493470     DOI: 10.1039/b516152e

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  11 in total

1.  Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy.

Authors:  Sherry R Chemler
Journal:  Curr Bioact Compd       Date:  2009-03-01

2.  Total synthesis of phenanthroindolizidine alkaloids (+/-)-antofine, (+/-)-deoxypergularinine, and their dehydro congeners and evaluation of their cytotoxic activity.

Authors:  Chung-Ren Su; Amooru G Damu; Po-Cheng Chiang; Kenneth F Bastow; Susan L Morris-Natschke; Kuo-Hsiung Lee; Tian-Shung Wu
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

3.  Synthesis of naphthalenes through three-component coupling of alkynes, Fischer carbene complexes, and benzaldehyde hydrazones via isoindole intermediates.

Authors:  Shaofeng Duan; Dilip K Sinha-Mahapatra; James W Herndon
Journal:  Org Lett       Date:  2008-03-20       Impact factor: 6.005

4.  Structural analogs of tylophora alkaloids may not be functional analogs.

Authors:  Wenli Gao; Annie Pei-Chun Chen; Chung-Hang Leung; Elizabeth A Gullen; Alois Fürstner; Qian Shi; Linyi Wei; Kuo-Hsiung Lee; Yung-Chi Cheng
Journal:  Bioorg Med Chem Lett       Date:  2007-11-21       Impact factor: 2.823

5.  Mild conditions for Pd-catalyzed carboamination of N-protected hex-4-enylamines and 1-, 3-, and 4-substituted pent-4-enylamines. Scope, limitations, and mechanism of pyrrolidine formation.

Authors:  Myra Beaudoin Bertrand; Joshua D Neukom; John P Wolfe
Journal:  J Org Chem       Date:  2008-10-23       Impact factor: 4.354

6.  Synthesis, biological evaluation and mechanism studies of deoxytylophorinine and its derivatives as potential anticancer agents.

Authors:  Haining Lv; Jinhong Ren; Shuanggang Ma; Song Xu; Jing Qu; Zhenjia Liu; Qing Zhou; Xiaoguang Chen; Shishan Yu
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

7.  Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.

Authors:  Ya-Qi Qiu; Cheng-Wei Yang; Yue-Zhi Lee; Ruey-Bing Yang; Chih-Hao Lee; Hsing-Yu Hsu; Chien-Chung Chang; Shiow-Ju Lee
Journal:  Oncotarget       Date:  2015-02-10

8.  Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus.

Authors:  Cheng-Wei Yang; Yue-Zhi Lee; Iou-Jiun Kang; Dale L Barnard; Jia-Tsrong Jan; Du Lin; Chun-Wei Huang; Teng-Kuang Yeh; Yu-Sheng Chao; Shiow-Ju Lee
Journal:  Antiviral Res       Date:  2010-08-19       Impact factor: 5.970

9.  Synthesis and antitumor activities of phenanthrene-based alkaloids.

Authors:  Songtao Li; Li Han; Liang Sun; Dan Zheng; Jiang Liu; Yingbo Fu; Xueshi Huang; Zhanyou Wang
Journal:  Molecules       Date:  2009-12-07       Impact factor: 4.411

10.  Use of chiral-pool approach into epi-thieno analogues of the scarce bioactive phenanthroquinolizidine alkaloids.

Authors:  Peter Šafář; Štefan Marchalín; Nadežda Prónayová; Viktor Vrábel; Ata Martin Lawson; Mohamed Othman; Adam Daïch
Journal:  Tetrahedron       Date:  2016-04-21       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.